✦ LIBER ✦

Evidence for the efficacy of peginterferon alfa-2a (40 KD) (PEGASYS) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors

✍ Scribed by W.Graham E. Cooksley; Teerha Piratvisuth; Yuan-Jen Wang; Varocha Mahachai; You-Chen Chao; Tawesak Tanwandee; Anuchit Chutaputti; Wen Yu Chang; Friederike E. Zahm; Nigel Pluck

Book ID: 118564933
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 165 KB
Volume: 36
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(02)80017-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

492 HBeAg and HBV DNA kinetics in HBeAg

492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB)

✍ M.W Fried; Y.E. Liaw; K.X. Luo; G.K.K. Lau; T. Piratvisuth; G. Cooksley; P. Marc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB

491 Peginterferon alpha-2a (40KD) (PEGAS

491 Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B (CHB)

✍ G. Cooksley; G.K.K. Lau; P. Marcellin; T. Piratvisuth; E. Bonino; K.X. Luo; S. H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 251 KB

PGI7 COST-EFFECTIVENESS OF PEGINTERFERON

PGI7 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) COMPARED TO LAMIVUDINE AS FIRST LINE TREATMENT OF CHRONIC HEPATITIS B (CHB) IN THE UK

✍ PL Veenstra; SD Sullivan; GM Dusheiko; M Jacobs; GJ Lewis; KK Patel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

O115 PEGINTERFERON LAMBDA FOR THE TREATM

O115 PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE

✍ Chan, H.L.; Ahn, S.H.; Chang, T.-T.; Peng, C.-Y.; Wong, D.; Coffin, C.S.; Lim, S 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

714 HBSAG LEVELS DURING THE FIRST 24 WEE

714 HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT

✍ I. Goulis; E. Akriviadis; S. Karatapanis; M. Deutsch; G. Dalekos; M. Raptopoulou 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

523 Effect of ALT flares on efficacy and

523 Effect of ALT flares on efficacy and safety of peginterferon α-2a (40 kDa) (PEGASYS®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 253 KB